New compound added to Basilea's clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025 Upfront payments of USD 2 million Ad hoc announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results